1067902-51-5

Basic information

• Product Name: 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridazine-3-carboxamide
• Synonyms: 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridazine-3-carboxamide
• CAS NO: 1067902-51-5
• Molecular Weight: 441.257
• Mol File: 1067902-51-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridazine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridazine-3-carboxamide(1067902-51-5)
• EPA Substance Registry System: 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridazine-3-carboxamide(1067902-51-5)

Safety Data

• Hazardous Substances Data: 1067902-51-5(Hazardous Substances Data)

Upstream product

• 869357-46-0 diethyl 2-(2-methyl-2-propionylhydrazono)malonate 
• 869357-54-0 4-hydroxy-1,5-dimethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 869357-55-1 4-chloro-1,5-dimethyl-6-oxopyridazine-3-carboxylic acid 
• 391212-29-6 O-(2-vinyloxyethyl)hydroxylamine 
• 934639-05-1 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid 

Relevant articles and documents

COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER

This invention relates to a combination product comprising a MEK inhibitor and a B-raf inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a combination product comprising a MEK inhibitor and a B raf inhibitor; a combination product comprising a kit of parts comprising a MEK inhibitor and a B-raf inhibitor; use of the combination product in the treatment of cancer; a method of treating cancer comprising administering the combination product to a patient. The combination product and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or B-raf.